Cassava Sciences
SAVA2.3800.00% ( 0.000 )
Cassava Sciences (SAVA)
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufil...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 2.380
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 4.980
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Cassava Sciences Analyst Rating
View MoreForecast & Rating
Nov 12, 2025Price forecast
$8.00236.13%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Mar 25 at 07:04 AM
Siav Corrects Key Deadlines for Extraordinary Shareholders’ Meeting
- CoinLive · Mar 24 at 06:47 AM
Circle Internet Partners with Cassava Technologies for Stablecoin Transactions in Africa
- benzinga_article · Mar 10 at 12:19 PM
Cassava Sciences shares are trading higher. The company announced it will rebrand as Filana Therapeutics with a new ticker symbol FLNA, effective March 11.
- Fiercepharma · Mar 10 at 10:10 AM
Filana leaves Cassava roots behind amid branch into epilepsy
- Market Beat · Mar 2 at 08:16 AM
Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Tuesday
- Unusual Whales · Feb 19 at 04:02 AM
Blood test predicts Alzheimer's 3-4 years in advance, according to FNIH Biomarkers Consortium study.
